EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF

18Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

EMMPRIN/CD147 is mainly known for its protease inducing function but a role in promoting tumor angiogenesis has also been demonstrated. This study provides evidence that EMMPRIN is a new coreceptor for the VEGFR-2 tyrosine kinase receptor in both endothelial and tumor cells, as it directly interacts with it and regulates its activation by its VEGF ligand, signalling and functional consequences both in vitro and in vivo. Computational docking analyses and mutagenesis studies identified a molecular binding site in the extracellular domain of EMMPRIN located close to the cell membrane and containing the amino acids 195/199. EMMPRIN is overexpressed in cancer and hence is able to further potentiate VEGFR-2 activation, suggesting that a combinatory therapy of an antiangiogenic drug together with an inhibitor of EMMPRIN/VEGFR-2 interaction may have a greater impact on inhibiting angiogenesis and malignancy.

Cite

CITATION STYLE

APA

Khayati, F., Pérez-Cano, L., Maouche, K., Sadoux, A., Boutalbi, Z., Podgorniak, M. P., … Mourah, S. (2015). EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF. Oncotarget, 6(12), 9766–9780. https://doi.org/10.18632/oncotarget.2870

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free